Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Cash from Investing Activities (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Cash from Investing Activities for 8 consecutive years, with -$28.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities fell 79.98% year-over-year to -$28.7 million, compared with a TTM value of -$17.3 million through Sep 2025, down 124.47%, and an annual FY2024 reading of $67.0 million, up 550.11% over the prior year.
  • Cash from Investing Activities was -$28.7 million for Q3 2025 at X4 Pharmaceuticals, down from $23.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $96.9 million in Q2 2024 and bottomed at -$28.7 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is $2.2 million, with a median of -$86000.0 recorded in 2021.
  • Peak annual rise in Cash from Investing Activities hit 2083.25% in 2024, while the deepest fall reached 59033.33% in 2024.
  • Year by year, Cash from Investing Activities stood at -$13000.0 in 2021, then crashed by 161.54% to -$34000.0 in 2022, then plummeted by 14114.71% to -$4.8 million in 2023, then plummeted by 78.38% to -$8.6 million in 2024, then plummeted by 232.55% to -$28.7 million in 2025.
  • Business Quant data shows Cash from Investing Activities for XFOR at -$28.7 million in Q3 2025, $23.1 million in Q2 2025, and -$3.1 million in Q1 2025.